| Autor: |
Hikoso, Shungo, Kida, Hirota, Sunaga, Akihiro, Nakatani, Daisaku, Okada, Katsuki, Dohi, Tomoharu, Sotomi, Yohei, Oeun, Bolrathanak, Sato, Taiki, Matsuoka, Yuki, Kitamura, Tetsuhisa, Yamada, Tomomi, Kurakami, Hiroyuki, Tamaki, Shunsuke, Seo, Masahiro, Yano, Masamichi, Hayashi, Takaharu, Nakagawa, Akito, Nakagawa, Yusuke, Yamada, Takahisa |
| Zdroj: |
Clinical Research in Cardiology; Jun2024, Vol. 113 Issue 6, p842-855, 14p |
| Abstrakt: |
Background: The effectiveness of β-blocker in patients with heart failure with preserved ejection fraction (HFpEF) remains to be determined. We aimed to clarify the association between the use of β-blocker and prognosis according to the status of frailty. Methods: We compared prognosis between HFpEF patients with and without β-blockers stratified with the Clinical Frailty Scale (CFS), using data from the PURSUIT-HFpEF registry (UMIN000021831). Results: Among 1159 patients enrolled in the analysis (median age, 81.4 years; male, 44.7%), 580 patients were CFS ≤ 3, while 579 were CFS ≥ 4. Use of β-blockers was associated with a worse composite endpoint of all-cause death and heart failure readmission in patients with CFS ≥ 4 (adjusted hazard ratio (HR) 1.43, 95% CI 1.10–1.85, p = 0.007), but was not significantly associated with this endpoint in those with CFS ≤ 3 (adjusted HR 0.95, 95% CI 0.71–1.26, p = 0.719) in multivariable Cox proportional hazard models. These results were confirmed in a propensity-matched analysis (HR in those with CFS ≥ 4: 1.42, 95% CI 1.05–1.90, p = 0.020; that in those with CFS ≤ 3: 0.83, 95% CI 0.60–1.14, p = 0.249), and in an analysis in which patients were divided into CFS ≤ 4 and CFS ≥ 5. Conclusions: Use of β-blockers was significantly associated with worse prognosis specifically in patients with HFpEF and high CFS, but not in those with low CFS. Use of β-blockers in HFpEF patients with frailty may need careful attention. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink